Log in

NYSEAMERICAN:CVRS - Corindus Vascular Robotics Stock Price, Forecast & News

$4.27
0.00 (0.00 %)
(As of 11/27/2019)
Today's Range
$4.27
Now: $4.27
$4.27
50-Day Range N/A
52-Week Range
$0.78
Now: $4.27
$4.40
VolumeN/A
Average Volume1.99 million shs
Market Capitalization$891.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVRS
Previous SymbolNYSEMKT:CVRS
CUSIPN/A
CIKN/A
Phone+1-508-6533335

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees90
Market Cap$891.08 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CVRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter.


Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions

What is Corindus Vascular Robotics' stock symbol?

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings data on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to analyst estimates of $3 million. View Corindus Vascular Robotics' Earnings History.

What price target have analysts set for CVRS?

1 brokers have issued twelve-month price objectives for Corindus Vascular Robotics' stock. Their forecasts range from $4.28 to $4.28. On average, they anticipate Corindus Vascular Robotics' stock price to reach $4.28 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Corindus Vascular Robotics.

What is the consensus analysts' recommendation for Corindus Vascular Robotics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corindus Vascular Robotics.

Has Corindus Vascular Robotics been receiving favorable news coverage?

News coverage about CVRS stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corindus Vascular Robotics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Corindus Vascular Robotics.

Who are some of Corindus Vascular Robotics' key competitors?

What other stocks do shareholders of Corindus Vascular Robotics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXC), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Helios and Matheson Analytics (HMNY), TherapeuticsMD (TXMD), Anavex Life Sciences (AVXL), Exelixis (EXEL) and NVIDIA (NVDA).

Who are Corindus Vascular Robotics' key executives?

Corindus Vascular Robotics' management team includes the folowing people:
  • Mr. Mark J. Toland, CEO, Pres & Director (Age 49)
  • Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 49)
  • Mr. Douglas Teany, Chief Operating Officer (Age 47)
  • Ms. Nora Dutta, Sr. VP of HR
  • Dr. J. Aaron Grantham, Chief Medical Officer of Cardiovascular

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corindus Vascular Robotics' stock price today?

One share of CVRS stock can currently be purchased for approximately $4.27.

How big of a company is Corindus Vascular Robotics?

Corindus Vascular Robotics has a market capitalization of $891.08 million. Corindus Vascular Robotics employs 90 workers across the globe.View Additional Information About Corindus Vascular Robotics.

What is Corindus Vascular Robotics' official website?

The official website for Corindus Vascular Robotics is http://www.corindus.com/.

How can I contact Corindus Vascular Robotics?

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.


MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  442 (Vote Underperform)
Total Votes:  821
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel